News - Gastro-intestinals, Remicade

Filter

Popular Filters

Global ulcerative colitis market to reach $6.6 billion by 2022

Global ulcerative colitis market to reach $6.6 billion by 2022

14-02-2014

The global ulcerative colitis market value will increase steadily over the coming years, increasing from…

AbbVieEntyvioGastro-intestinalsGlobalHumiraJohnson & JohnsonMarkets & MarketingPharmaceuticalRemicadeSimponi InjectionTakeda Pharmaceuticals

Modest growth forecast for global Crohn’s disease market

Modest growth forecast for global Crohn’s disease market

04-02-2014

The global Crohn’s disease (CD) market value is forecast to show modest growth, climbing from $3.2…

AbbVieBiotechnologyEntyvioGastro-intestinalsGlobalHumiraJohnson & JohnsonMarkets & MarketingPharmaceuticalRemicadeStelara InjectionTakeda Pharmaceuticals

Promising late-stage GI drugs could stabilize global market decline; report

16-01-2014

The gastrointestinal (GI) therapeutics market for irritable bowel syndrome (IBS), ulcerative colitis…

BiosimilarsGastro-intestinalsGlobalMarkets & MarketingPharmaceuticalRemicadeTakeda Pharmaceuticalsvedolizumab

Ranbaxy and EPIRUS sign licensing agreement for Infliximab biosimilar

Ranbaxy and EPIRUS sign licensing agreement for Infliximab biosimilar

09-01-2014

India's largest drugmaker Ranbaxy Laboratories (BSE: 500359) and EPIRUS Switzerland, a wholly-owned subsidiary…

Anti-Arthritics/RheumaticsBiosimilarsEPIRUS BiopharmaceuticalsGastro-intestinalsIndiainfliximabLicensingRanbaxy LaboratoriesRemicade

Vedolizumab has potential to offer improvement over infliximab in UC

30-04-2013

Surveyed US and EU5 gastroenterologists agree that new moderate to severe ulcerative colitis (UC) therapies…

EuropeGastro-intestinalsinfliximabJanssenMarkets & MarketingMerck & CoNorth AmericaPharmaceuticalRemicadeTakeda Pharmaceuticalsvedolizumab

US gastroenterologists increasingly using biologics to treat Crohn's patients in remission

06-03-2013

Although there have been no significant changes with regard to biologic treatment and Crohn's disease…

AbbVieBiotechnologyCimziaGastro-intestinalsHumiraJanssenMarkets & MarketingNorth AmericaPharmaceuticalRemicadeUCB

Uptake of biosimilars will see Remicade and Humira sales decline in 2017

26-09-2012

The TNF-alpha inhibitors infliximab (Janssen Biotech/Merck/Mitsubishi Tanabe's Remicade) and adalimumab…

BiotechnologyGastro-intestinalsGenericsGlobalHumiraMarkets & MarketingRemicade

US gastroenterologists' attitudes to prescribing for Crohn's disease and ulcerative colitis

09-09-2012

When evaluating the most important attributes for emerging therapies for Crohn's disease (CD) and ulcerative…

BiotechnologyGastro-intestinalsHumiraMarkets & MarketingNorth AmericaRemicadeSimponi Injectionvedolizumab

Ulcerative colitis drug market to reach $3 billion by 2020

02-05-2012

The ulcerative colitis drug market will experience moderate growth over the next decade, increasing from…

Gastro-intestinalsHumiraMarkets & MarketingPharmaceuticalRemicadeSimponi Injectiontofacitinibvedolizumab

Merck & Co gets positive CHMP opinion for Remicade in new indication

22-01-2012

US drug giant Merck & Co (NYSE: MRK) says that announced that the European Medicines Agency’s Committee…

EuropeGastro-intestinalsMerck & CoPharmaceuticalRegulationRemicade

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top